Examen
Sinovac Information Pack Case study: Sinovac’s PiCoVacc COVID-19 vaccine
- Cours
- Établissement
Sinovac Information Pack Case study: Sinovac’s PiCoVacc COVID-19 vaccine
[Montrer plus]
Vendeur
S'abonner
ACTUALSTUDY
Avis reçus
Aperçu du contenu
Case study: Sinovac’s PiCoVacc COVID-19 vaccine Phase 3 OngoingR&D commencement: January 2
In-clinic: Humans dosed: 744 (expected Pha
Phase II Funding disclosed: N/A
Vaccine type: Inactivated vaccin
Asset overview
PiCoVacc is a COVID-19 vaccine candidate based on a chemically inactivated formulation of the SARS-CoV-2 virus developed by Sinovac
PiCoVacc uses a proven formulation that induces a SARS-CoV-2-specific neutralizing antibody response, conferring immunity
Sinovac has partnered with Dynavax to use their CPG 1018 adjuvant, which boosts the immune response to inactivated vaccines (e.g., HEPLIS
Development timeline
Sinovac announced the beginning of a combined Phase I/Phase II clinical trial on April 20, 2020
Sinovac recently expanded its manufacturing capabilities by acquiring space and funding; over 70K square meters of land were acquired in add
to funding from the Bank of Beijing to prepare for scaled production
Reasons for optimism
The antibodies generated by PiCoVacc appear to be effective against multiple known mutations of the virus, and have shown promise in trials o
macaques
No evidence of antibody-dependent enhancement, an occasional side effect in which some antibodies generated by a vaccine can be beneficia
the virus
, Phase 3 Ong
Case study: Sinopharm/Wuhan Institute of Virology’s inactivated vaccine can
R&D commencement: Q1 202
In-clinic: Humans dosed: 96 (expected Pha
Phase II Funding disclosed: $141M
Vaccine type: Inactivated vaccin
Asset overview
The COVID-19 vaccine candidate developed by Sinopharm/Wuhan Institute of Virology is based on an inactivated formulation of the SARS-CoV
virus
Chinese state-owned pharmaceutical group Sinopharm has partnered with the Wuhan Institute of Virology to co-develop their first inactivated va
which induces a SARS-CoV-2-specific neutralizing antibody response
Development timeline
First and second phases of the trial for the vaccine candidate were launched in April 2020, with trial participants from the first phase still under
observation
Chairman of Sinopharm, Liu Jingzhen, stated that a fund of 1B yuan (~$141M) has been set up to support vaccine R&D efforts
Sinopharm intends to conduct the third phase of the trial and expects that the safety and efficacy study will take one year to complete all three
phases
Reasons for optimism
Phase I of trials for the vaccine candidate has demonstrated a strong safety profile so far
Sinopharm’s inactivated vaccine is the third COVID-19 vaccine candidate to be approved in China; once successfully synthesized, inactivated
vaccines can be produced on a large scale while other types of vaccines developed using new technologies are limited due to a lack of product
capacity
, Phase 3 O
Case study: Sinopharm/Beijing Biological Products’ inactivated vaccine candidate
R&D commencement: April 202
In-clinic: Humans dosed: N/A
Phase II Funding disclosed: N/A
Vaccine type: Inactivated vaccin
Asset overview
The COVID-19 vaccine candidate is based on an inactivated formulation of the SARS-CoV-2 virus (specifically using Vero cells)
Chinese state-owned pharmaceutical group Sinopharm has partnered with Beijing Tiantan Biological Products to co-develop this inactivated vac
(in addition to the vaccine developed in partnership with Wuhan Institute)
Development timeline
There is little information on the Sinopharm/Beijing Tiantan vaccine partnership; according to the Chinese Clinical Trial Registry, the study regist
was filed at the end of April
However, Sinopharm has been actively working on other COVID-19 vaccines that can potentially be leveraged for this project
Reasons for optimism
Sinopharm already has two potential vaccines in the pipeline through partnerships with other institutes in China
,
Les avantages d'acheter des résumés chez Stuvia:
Qualité garantie par les avis des clients
Les clients de Stuvia ont évalués plus de 700 000 résumés. C'est comme ça que vous savez que vous achetez les meilleurs documents.
L’achat facile et rapide
Vous pouvez payer rapidement avec iDeal, carte de crédit ou Stuvia-crédit pour les résumés. Il n'y a pas d'adhésion nécessaire.
Focus sur l’essentiel
Vos camarades écrivent eux-mêmes les notes d’étude, c’est pourquoi les documents sont toujours fiables et à jour. Cela garantit que vous arrivez rapidement au coeur du matériel.
Foire aux questions
Qu'est-ce que j'obtiens en achetant ce document ?
Vous obtenez un PDF, disponible immédiatement après votre achat. Le document acheté est accessible à tout moment, n'importe où et indéfiniment via votre profil.
Garantie de remboursement : comment ça marche ?
Notre garantie de satisfaction garantit que vous trouverez toujours un document d'étude qui vous convient. Vous remplissez un formulaire et notre équipe du service client s'occupe du reste.
Auprès de qui est-ce que j'achète ce résumé ?
Stuvia est une place de marché. Alors, vous n'achetez donc pas ce document chez nous, mais auprès du vendeur ACTUALSTUDY. Stuvia facilite les paiements au vendeur.
Est-ce que j'aurai un abonnement?
Non, vous n'achetez ce résumé que pour €7,76. Vous n'êtes lié à rien après votre achat.
Peut-on faire confiance à Stuvia ?
4.6 étoiles sur Google & Trustpilot (+1000 avis)
81113 résumés ont été vendus ces 30 derniers jours
Fondée en 2010, la référence pour acheter des résumés depuis déjà 14 ans